Role of IRF4 in resistance to immunomodulatory (IMid) compounds(®) in Waldenström’s macroglobulinemia

BACKGROUND: Immunomodulatory drugs, IMid compounds, are active in Waldenström's macroglobulinemia (WM), although in a lesser extent than multiple myeloma, where it was initially developed. We hypothesized WM tumour cells might develop mechanisms of resistance, and sought to identify and describ...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncotarget
Autori principali: Bertrand, Elisabeth, Jouy, Nathalie, Manier, Salomon, Fouquet, Guillemette, Guidez, Stéphanie, Boyle, Eileen, Noel, Stéphanie, Tomowiak, Cécile, Herbaux, Charles, Schraen, Susanna, Preudhomme, Claude, Quesnel, Bruno, Poulain, Stéphanie, Leleu, Xavier
Natura: Artigo
Lingua:Inglês
Pubblicazione: Impact Journals LLC 2017
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5762562/
https://ncbi.nlm.nih.gov/pubmed/29348877
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22872
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi